Detection of VipAlbumin® Effect in CD34 and SDF-1 Mobilization, in Streptozotocin-induced Diabetes Mellitus Mice

Authors

  • Andi Rizki Adi Pradana Master Program of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya
  • Muhammad Sasmito Djati Dept. of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya
  • Muhaimin Rifa'i Dept. of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya

DOI:

https://doi.org/10.21776/ub.jels.2015.005.01.03

Abstract

Diabetes mellitus is a disease in which the body loses its ability to provide tight regulation and maintain a dynamic interaction between the tissue sensitivity and insulin secretion by β cells. The impact of this dysfunctional mechanism is uncontrolled blood glucose levels that lead to hyperglycemia condition. Highly reactive free radicals have a strong involvement in the pathogenesis of diabetes mellitus, where one of its forming process may be triggered by hyperglycemia condition. Patients with diabetes mellitus itself vulnerable to endothelial dysfunction, which is caused by a decrease in circulating endothelial progenitor cells, and also a decrease in chemokines which play a role in affecting the activities of these cells. Hyperglycemia condition and free radical activity is a major cause of these endothelial progenitor cells dysfunction.The purpose of this study was to determine the role of VipAlbumin®, a supplement derived from Channa striatus albumin extracts in inhibiting the action of free radicals that are formed due to hyperglycemia condition, which can affect the increase in endothelial progenitor cells relative amount. This study used BALB/C mice that induced to undergo diabetes mellitus through streptozotocin injection intraperitoneally at 5-day old. Mice who have reached 4 week old and positive to diabetes mellitus (blood glucose levels > 200 mg.dl-1) will be administered with VipAlbumin® orally for 14 days. VipAlbumin® dosage was divided into 4 groups: positive control (without VipAlbumin®); 1st dose (0.01664 mg.gr-1 BW); 2nd dose (0.416 mg.gr-1 BW); 3rd dose (10.4 mg.gr-1 BW). The last step was flow cytometric analysis to determine the development of endothelial progenitor cells relative amount, which isolated from bone marrow. The variables measured in this study were the relative amount of CD34+ and SDF-1. Based to flow cytometric analysis, mice with VipAlbumin® administration did not show any significant improvement in CD34 relative amount when compared to the positive control. Relative amount of Chemokine SDF-1 itself, although only occur at the 3rd dose of VipAlbumin® treatment, has increased and significantly different from the positive control.

Keywords: CD34, diabetes mellitus, free radicals, hyperglycemia, SDF-1, streptozotocin, VipAlbumin®

Downloads

Published

2015-09-30

Issue

Vol. 5 No. 1 (2015)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).